---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007752"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T12:04:46.041453+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Armata Q1 net loss $6.5M, cash $11.7M; AP-SA02 Phase 1b/2a topline due H1 2025

## Summary
- Net loss of $6.5M ($0.18 basic EPS) vs $25.0M loss in Q1 2024; includes $5.2M non-cash gain on convertible loan.
- Cash and equivalents $11.7M at March 31, 2025, up from $9.3M at Dec 31, 2024; 36.2M shares outstanding.
- Topline results from Phase 1b/2a diSArm study of intravenous AP-SA02 for S. aureus bacteremia expected in first half 2025.
- Received additional $4.65M non-dilutive DoD/MTEC funding to support AP-SA02 Phase 2 close-out and FDA end-of-Phase 2 meeting.
- Entered $10.0M secured credit agreement with Innoviva; existing Innoviva credit agreements extended to March 12, 2026.

## SEC filing metadata
- accession: 0001558370-25-007752
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/0001558370-25-007752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837025007752/armp-20250514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007752
- JSON: https://secwatch.observer/filing/0001558370-25-007752.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.